Free Trial

Brainstorm Cell Therapeutics (BCLI) Competitors

Brainstorm Cell Therapeutics logo
$0.72 +0.03 (+4.06%)
As of 03:58 PM Eastern

BCLI vs. AADI, PRLD, LIAN, GRCE, NBRV, XCUR, SCLX, MURA, OSTX, and LTRN

Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Aadi Bioscience (AADI), Prelude Therapeutics (PRLD), LianBio (LIAN), Grace Therapeutics (GRCE), Nabriva Therapeutics (NBRV), Exicure (XCUR), Scilex (SCLX), Mural Oncology (MURA), OS Therapies (OSTX), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry.

Brainstorm Cell Therapeutics vs. Its Competitors

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Brainstorm Cell TherapeuticsN/A N/A -519.50%
Aadi Bioscience -246.06%-71.87%-57.28%

In the previous week, Brainstorm Cell Therapeutics had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Brainstorm Cell Therapeutics and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Brainstorm Cell Therapeutics' score of -0.02 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company Overall Sentiment
Brainstorm Cell Therapeutics Neutral
Aadi Bioscience Neutral

Aadi Bioscience has a consensus target price of $1.67, indicating a potential downside of 14.09%. Given Aadi Bioscience's higher possible upside, analysts clearly believe Aadi Bioscience is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aadi Bioscience
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.36-0.21
Aadi Bioscience$25.07M1.91-$65.76M-$2.35-0.83

Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aadi Bioscience beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCLI vs. The Competition

MetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.06M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-0.2121.2028.0820.03
Price / SalesN/A338.37460.87103.88
Price / CashN/A43.2336.5559.01
Price / Book-0.538.338.645.90
Net Income-$11.62M-$55.19M$3.24B$258.66M
7 Day Performance-16.02%5.85%4.11%2.20%
1 Month Performance-39.15%17.58%10.74%12.75%
1 Year Performance-86.92%5.05%34.43%19.27%

Brainstorm Cell Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCLI
Brainstorm Cell Therapeutics
1.1478 of 5 stars
$0.72
+4.1%
N/A-87.2%$7.06MN/A-0.2140Analyst Downgrade
AADI
Aadi Bioscience
0.3993 of 5 stars
$1.91
-3.0%
$1.67
-12.7%
+28.0%$47.17M$25.07M-0.8440
PRLD
Prelude Therapeutics
3.6924 of 5 stars
$0.82
+0.7%
$4.50
+448.8%
-84.4%$46.30M$7M-0.49120Positive News
LIAN
LianBio
N/A$0.43
+3.5%
N/A-82.6%$46.09MN/A-0.53110
GRCE
Grace Therapeutics
1.7944 of 5 stars
$3.31
-3.8%
$12.00
+262.5%
N/A$45.78MN/A-3.72N/APositive News
High Trading Volume
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
XCUR
Exicure
1.346 of 5 stars
$7.03
-3.3%
N/A+1,945.6%$44.42MN/A-1.8450Gap Up
SCLX
Scilex
2.381 of 5 stars
$6.32
-2.2%
$455.00
+7,099.4%
-82.1%$43.94M$50.71M-0.2280News Coverage
MURA
Mural Oncology
3.4411 of 5 stars
$2.54
+4.1%
$12.00
+372.4%
-28.3%$43.87MN/A-0.33119
OSTX
OS Therapies
2.0581 of 5 stars
$1.56
-8.2%
$18.00
+1,053.8%
N/A$43.83MN/A-1.81N/A
LTRN
Lantern Pharma
3.0762 of 5 stars
$3.99
+8.4%
$25.00
+526.6%
-3.6%$43.01MN/A-2.1720Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:BCLI) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners